ArticleNaunyn-Schmiedeberg's archives of pharmacology2024
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Contribution of the Serotonin 5-HTNeuropsychopharmacology reports · 2026Article
- Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.British journal of pharmacology · 2026Review
- Temporal assessment of behavior in Parkinson's visual hallucinations via a multidimensional analysis strategy.Signal transduction and targeted therapy · 2026Article
- Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential.Molecular psychiatry · 2026Article
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- An exploration of the relationships between the effects of psilocybin on behavior, 5-HTJournal of psychopharmacology (Oxford, England) · 2026Article
- Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.Fundamental & clinical pharmacology · 2025Review
- The DRN-VLO pathway via distinct 5-HT synaptic mechanisms modulates neuropathic pain-induced depressive-like behaviors in mice.The journal of headache and pain · 2025Article
- Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress.Translational psychiatry · 2025Article
- Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.Nature neuroscience · 2025Article
- A multi-institutional investigation of psilocybin's effects on mouse behavior.bioRxiv : the preprint server for biology · 2025Article
- Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways.Pharmacology research & perspectives · 2025Article
- Structural basis for psilocybin biosynthesis.Nature communications · 2025Article
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.Brain sciences · 2025Review
- Potential Differences in Psychedelic Actions Based on Biological Sex.Endocrinology · 2024Review
- 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.ACS pharmacology & translational science · 2024Review
- Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.bioRxiv : the preprint server for biology · 2024Article
- CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.Journal of psychiatry & neuroscience : JPNReview
Corrections and comments
- Erratum issued
- Update of
Authors and funding
13 authors at 2 institutions in 2 countries.
Rika Takaba *Department of Chemical Pharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan, 468-8502. 140973239@ccalumni.meijo-u.ac.jp.
Daisuke Ibi *Department of Chemical Pharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan, 468-8502. ibid@meijo-u.ac.jp.
Keisuke YoshidaDepartment of Medical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Eri HosomiDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Ririna KawaseDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Hiroko KitagawaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Hirotaka GotoDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Mizuki AchiwaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Kento MizutaniDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Kyosuke MaedaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Javier González-MaesoDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.
Shinji KitagakiDepartment of Medical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 468-8502.
Masayuki HiramatsuDepartment of Chemical Pharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan, 468-8502. mhiramt@meijo-u.ac.jp.
Meijo University · JPVirginia Commonwealth University · US
Funding
Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8MJapan Society for the Promotion of Science 15H06719, 16K19786, 19K07332, and 22K06872Nagai Memorial Research Scholarship 223903NIH grant R01MH084894NIMH NIH HHS R01 MH084894YOKOYAMA Foundation for Clinical Pharmacology YRY-1909
Abstract
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT
Indexed as
AmphetaminesAntidepressive AgentsBridged Bicyclo CompoundsHallucinogensMethylaminesMice, Inbred C57BLPsilocybinReceptor, Serotonin, 5-HT2AAnimalsAnti-Anxiety AgentsBehavior, AnimalDepressionMaleMiceMotor ActivitySerotonin 5-HT2 Receptor Agonists(4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine4-iodo-2,5-dimethoxyphenylisopropylamineAmphetaminesAnti-Anxiety AgentsAntidepressive AgentsBridged Bicyclo CompoundsHallucinogensMethylaminespsilocinPsilocybinReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsDOIMajor depressive disorderPsilocin (psilocybin)Serotonergic psychedelicsTCB-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.